Technology
Health
Biotechnology

Unity Biotechnology

$8.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-2.20%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell UBX and other stocks, options, ETFs, and crypto commission-free!

About

Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.

Employees
106
Headquarters
Brisbane, California
Founded
2009
Market Cap
339.31M
Price-Earnings Ratio
β€”
Dividend Yield
β€”
Average Volume
181.43K
High Today
$8.62
Low Today
$7.90
Open Price
$8.16
Volume
135.47K
52 Week High
$24.56
52 Week Low
$7.90

Collections

Technology
Health
Biotechnology
Research And Development
Therapy
2018 IPO
US
North America

News

Seeking AlphaMar 7

Cantor likes Unity Biotech, shares up 15% premarket

Thinly traded micro cap Unity Biotechnology (NASDAQ:UBX) is up 15% premarket, albeit on only 641 shares, on the heels of new coverage by Cantor Fitzgerald.

279
Associated PressMar 4

UNITY Biotechnology, Inc. to Participate in the Cowen 39th Annual Health Care Conference

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (β€œUNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today...

130
MarketBeatFeb 27

Stock Price, News, & Analysis for Unity Biotechnology

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was foun...

8

Earnings

-$4.69
-$3.27
-$1.85
-$0.43
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected Jun 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.